Estring

Short answer: Bioidentical hormone replacement therapy (BHRT) can be safe and effective for treating menopausal symptoms when prescribed and monitored appropriately — but there’s an important distinction doctors make between FDA‑approved “bioidentical” hormones and unregulated compounded BHRT. Most professional medical societies recommend FDA‑approved products and caution about compounded preparations. Key points doctors and medical organizations say “Bioidentical” simply means the hormone molecule is chemically identical to the human hormone (e.g., 17β‑estradiol, micronized progesterone). That alone doesn’t guarantee safety. FDA‑approved bioidentical hormones (standard prescription products) have documented dosing, quality control, and clinical-trial data on benefits and risks. Clinicians generally prefer these because they are regulated and tested. Compounded BHRT (custom creams, troches, gels made by compounding pharmacies) lacks the same regulation and consistent dosing. Major bodies — North American Menopause Society (NAMS), American College of Obstetricians and Gynecologists (ACOG), the Endocrine Society and the FDA — warn that claims about “customized” or “safer/natural” compounded hormones are not well supported by evidence. Risks of hormone therapy depend on type/dose/route and patient factors (age, time since menopause, medical history). Known risks of systemic estrogen (especially combined estrogen–progestin) include increased risk of blood clots, stroke, and, with long‑term use, possible increased breast cancer risk. Transdermal estrogen may have lower clot risk than oral estrogen; micronized progesterone may have a more favorable profile than some synthetic progestins. Saliva hormone testing (often marketed by BHRT clinics) is unreliable for guiding dosing; most doctors do not use it for management. Practical, doctor‑oriented guidance If you and your clinician decide on hormone therapy, prefer FDA‑approved, regulated products when possible (predictable dosing, safety data). Use the lowest effective dose for symptoms and reassess regularly. If you have a uterus and are taking systemic estrogen, you need an appropriate progestogen to protect the endometrium. Discuss personal risk factors (breast cancer history, clotting disorders, cardiovascular disease, liver disease, smoking) before starting. Get regular follow‑up: symptom review, screening (mammography), and labs guided by your clinician. Specific FDA‑approved products doctors commonly use (examples) Estradiol (oral/transdermal/vaginal): Estrace (oral), Climara / Estraderm / Vivelle‑Dot / Alora (patches), Vagifem (vaginal tablet), Estring (vaginal ring) Micronized progesterone: Prometrium (oral); Crinone, Endometrin (vaginal progesterone preparations) Combination product: Bijuva (oral estradiol + progesterone capsule) Testosterone (for men: AndroGel, Testim, Androderm — for women, testosterone therapy is off‑label and used cautiously with limited evidence) If you’re considering compounded BHRT Be cautious. Ask the prescriber why a compounded product is needed instead of an FDA‑approved product. If you still choose compounding, use a pharmacy accredited by the Pharmacy Compounding Accreditation Board (PCAB) or one with strong quality control, and request certificates of analysis and USP compliance. Expect close follow‑up and objective clinical endpoints (symptoms, safety monitoring) rather than saliva tests. Trusted resources and organizations North American Menopause Society (NAMS) — position statements and patient info American College of Obstetricians and Gynecologists (ACOG) The Endocrine Society FDA consumer information on BHRT and compounded hormones Major medical centers: Mayo Clinic, Cleveland Clinic (reliable patient guides) Bottom line BHRT can be a safe, effective option if you use evidence‑based, FDA‑approved hormones under a clinician’s supervision and with appropriate monitoring. Be skeptical of claims that compounded BHRT is inherently safer or more “natural,” and avoid saliva testing as a dosing guide. Talk with a gynecologist, endocrinologist, or a menopause specialist about which option fits your symptoms and risks. If you’d like, tell me your age, symptoms, medical history (e.g., history of clotting, breast cancer, heart disease), and whether you’re already on any hormones — I can help summarize the pros and cons for your situation and suggest questions to ask a clinician.

Mentioned in position 7 of 19

Short answer BHRT = bioidentical hormone replacement therapy. It means replacing hormones (usually estradiol/estrogen, progesterone, and sometimes testosterone) with compounds that have the same chemical structure as human hormones. It’s used most often for menopausal or perimenopausal symptoms (hot flashes, night sweats, vaginal dryness, low libido) and for some people with age‑related low testosterone. Whether you “need” it depends on your symptoms, medical history, and risk factors — a clinician should evaluate you and discuss benefits, risks and alternatives. What BHRT is, in plain language “Bioidentical” refers to hormones that are chemically identical to human hormones (for example, 17β‑estradiol, micronized progesterone). BHRT can be prescribed as FDA‑approved products (patches, pills, vaginal tablets/gels, injections) or made by compounding pharmacies (custom creams, pellets, combinations). Delivery options: transdermal patch or gel, oral pills, vaginal tablets or rings, injections, and subcutaneous pellets. How BHRT is different from other hormone therapy Conventional HRT may use the same bioidentical molecules (many common estrogen and progesterone products are bioidentical) or synthetic/animal‑derived progestins. The major distinction often discussed is compounded (non‑FDA) “custom” BHRT vs. FDA‑approved preparations. FDA products have quality control and standardized dosing; compounded products do not have the same regulatory oversight and may be less predictable. Who might be a candidate Menopausal or perimenopausal people with bothersome vasomotor symptoms (hot flashes, night sweats) or urogenital symptoms that affect quality of life. People with premature ovarian insufficiency or surgical menopause. Men or women with clinically confirmed low testosterone and related symptoms (low libido, low energy), after careful assessment. When BHRT is generally not recommended (important contraindications) Active or recent breast cancer (unless cleared by oncology), estrogen‑sensitive cancers without oncology approval. Unexplained vaginal bleeding. Active or history of venous thromboembolism (blood clots), recent stroke or heart attack (needs specialist evaluation). Untreated severe liver disease. Always discuss risks with your clinician. What the evidence and risks say (brief) BHRT can effectively reduce hot flashes, night sweats and help vaginal dryness; testosterone can help sexual function in some women. Risks depend on hormone type, dose, route and the person’s age/risk profile. Transdermal estrogen has lower clot risk than oral; combined estrogen‑progestin was associated with increased breast cancer and cardiovascular risks in some studies (risks vary by age and timing of start). Long‑term outcomes are individualized and should be discussed with your clinician. Typical evaluation and monitoring Clinical history and symptom assessment; family history of breast/ovarian cancer; cardiovascular risk assessment. Baseline recommended tests often include: mammogram (if due), blood pressure, fasting lipid panel, glucose/A1c, and possibly hormone labs (estradiol, FSH, total testosterone, SHBG) — note: hormone levels fluctuate in perimenopause and are not always definitive. For some therapies (compounded testosterone), monitoring serum levels is used. Ongoing monitoring: symptom response, side effects, regular mammography and pelvic care as recommended, periodic reassessment of dose/need. Alternatives or adjuncts Nonhormonal treatments for hot flashes: SSRIs/SNRIs (venlafaxine, paroxetine), gabapentin, clonidine, lifestyle changes. Local vaginal estrogen (vaginal tablet/creams/rings) for urogenital symptoms with minimal systemic absorption. Lubricants/moisturizers for vaginal dryness. Brands and services (recommendations and why) Estradiol patches: Vivelle‑Dot, Climara — transdermal delivery reduces first‑pass liver effects and tends to have lower VTE risk than oral estrogen. Vaginal/local estrogen: Vagifem (vaginal tablets), Estring or other local rings — effective for local vaginal atrophy with low systemic exposure. Micronized progesterone: Prometrium — an FDA‑approved bioidentical progesterone option commonly used for endometrial protection with estradiol. Testosterone gels (when appropriate and prescribed): AndroGel, Testim — used more often in men; testosterone therapy for women is off‑label and requires specialist oversight and monitoring. For reliable, evidence‑based care and evaluation: Mayo Clinic Menopause Clinic, Cleveland Clinic Menopause Program, or any clinician certified or listed by the North American Menopause Society (NAMS) — these centers follow guidelines and can individualize care. If considering compounded BHRT: use only accredited compounding pharmacies (look for those accredited by the Pharmacy Compounding Accreditation Board/PCAB) and discuss with a clinician experienced in BHRT; be aware compounded products are not FDA‑approved and dose/absorption can vary. How to decide next (practical steps) Make a list of symptoms, duration, how they affect daily life, and any medications and major medical history (clots, breast cancer, heart disease). Schedule an appointment with your primary care clinician, gynecologist, endocrinologist or a menopause specialist (NAMS‑listed). Ask about risks/benefits tailored to you. If you and your clinician decide to try BHRT, prefer FDA‑approved preparations when possible and start with the lowest effective dose; arrange baseline screening (mammogram, labs) and a monitoring plan. If considering compounded BHRT or pellet therapy, discuss the limited evidence and quality variability and get labs and follow‑up monitoring set up. If you want, tell me: your age, sex/gender, main symptoms, and relevant medical history (breast cancer, blood clots, heart disease), and I can outline what a clinician will likely check and what options may be appropriate for you.

Mentioned in position 4 of 7

Short answer If you want the strongest evidence for safety, quality and known dosing, ask your clinician about FDA‑approved (traditional) HRT first — e.g., transdermal estradiol patches (Vivelle‑Dot, Climara), oral estradiol (Estrace), low‑dose vaginal estrogen (Estring, Vagifem) and micronized progesterone (Prometrium). If you want a customized formulation and are willing to accept less regulatory oversight and less rigorous safety data, ask about compounded “bioidentical” hormone therapy (BHRT) — but only from an experienced menopause clinician working with an accredited compounding pharmacy and with careful monitoring. Why (short) Traditional HRT: standardized dosing, FDA manufacturing and safety data, large trials and guideline recommendations. BHRT: may be tailored (dose/route/combination) and marketed as “natural,” but clinical evidence of superiority is lacking and formulations are not FDA‑approved or uniformly regulated. What to ask your clinician (things to say or bring up) Describe your symptoms, goals and medical history (breast cancer history, blood clotting, heart disease, stroke, migraines, smoking). Ask: “What are the proven benefits and risks of the hormone options for someone with my medical history?” Ask about routes and why one is preferred (e.g., transdermal estradiol may have lower clot risk than oral). If a clinician recommends BHRT, ask which lab tests they’ll use (avoid relying only on saliva tests), how dose is determined, which compounding pharmacy they use, how quality/consistency is verified, and what follow‑up and safety monitoring they’ll do. Ask about non‑hormonal alternatives and about vaginal (local) vs systemic therapy for genitourinary symptoms. Where to go / who to see (specific places and why) Primary options for evidence‑based care: Your gynecologist or primary care physician — many manage menopause/HRT. Menopause specialists: use the North American Menopause Society (NAMS) “Find a Menopause Practitioner” to locate clinicians with menopause expertise. NAMS‑trained clinicians follow current guideline recommendations. Major centers with menopause programs: Mayo Clinic, Cleveland Clinic Center for Menopause, Johns Hopkins Women’s Health — these centers have multidisciplinary teams and up‑to‑date protocols. If you prefer BHRT/compounded hormones: Use a clinician experienced in menopause who understands the limits of the evidence and who uses appropriate testing and monitoring. Ask them to work with an accredited compounding pharmacy. Look for compounding pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or URAC. Examples often used nationally (check current accreditation first): Wedgewood Pharmacy (Wedgewood Compounding), Empower Pharmacy, Fagron. Don’t pick a pharmacy just because it advertises “bioidentical” — verify accreditation and sterility/quality checks. For telehealth/concierge options: Some reputable telemedicine services and menopause clinics now provide HRT (traditional or compounded) with remote follow‑up — check credentials and ask about lab monitoring and local lab partnerships. Examples: Evexia (clinic networks vary), Maven Clinic (women’s health telehealth), or established academic centers that offer virtual consults. Verify the provider’s board certification and menopause training. Practical tips and safety checks Prefer FDA‑approved products when possible for systemic therapy; use low‑dose vaginal estrogen for local symptoms. If you have risk factors for blood clots, cardiovascular disease, or breast cancer, discuss alternatives and risk mitigation (route selection, lowest effective dose, duration). Avoid clinicians who base dosing solely on saliva hormone tests — these are not recommended for systemic HRT dosing. Blood tests and symptom response plus guideline‑driven risk assessment are standard. Get baseline screening as indicated (mammogram, blood pressure, lipids, glucose/HbA1c, liver tests, pregnancy test if relevant) and schedule regular follow‑up visits after starting therapy. Bottom line Start the conversation with a clinician experienced in menopause: ask first about evidence‑based, FDA‑approved HRT options and whether those meet your goals and risk profile. If you still prefer BHRT for specific reasons, insist on an evidence‑minded prescriber, accredited compounding pharmacy, clear monitoring plan, and informed consent about the limits of safety data. If you want, tell me your age, symptoms and major medical history (e.g., prior breast cancer, clotting disorder, heart disease, smoking) and I can suggest more targeted questions and which specific products/routes are most likely to be recommended.

Mentioned in position 4 of 13

Do you mean hormone replacement for menopause (to treat hot flashes, night sweats, vaginal dryness and protect bone) or gender‑affirming HRT? The answer and next steps are different for each, so I can be more specific once you tell me which you mean. Short answer (menopause): No — being in your late 50s is usually not “too late” to start menopausal HRT if you have bothersome symptoms or want bone protection. Whether it’s appropriate depends on your personal and family medical history (cardiovascular disease, stroke, blood clots, breast cancer, smoking, liver disease, etc.), how long it’s been since your last period, and which formulation you use. Many guidelines say benefits generally outweigh risks for people under about 60 or within roughly 10 years of menopause, but treatment can still be considered later with individualized assessment. What to know and do next (menopausal HRT) Benefits: very effective for vasomotor symptoms (hot flashes/night sweats), improves sleep and vaginal symptoms, reduces bone loss and fracture risk. Main risks: small increased risks of stroke and blood clots (higher with oral estrogens and with older age), and increased breast cancer risk with longer-term combined estrogen+progestogen therapy. Transdermal estradiol has lower clot risk than oral. Types/choices: Systemic estrogen: oral (estradiol/Estrace, conjugated estrogens/Premarin), transdermal patches (Vivelle‑Dot, Climara), or gels (EstroGel). Transdermal (patch/gel) often preferred if clot/CV risk is a concern. If you still have a uterus, you’ll usually need a progestogen added to protect the endometrium (levonorgestrel IUD such as Mirena is a common option). For mainly vaginal symptoms, lower‑dose local treatments (vaginal estradiol tablets like Vagifem, rings like Estring, or creams) provide benefit with minimal systemic absorption. Workup before starting: medical history, blood pressure, BMI, smoking status, family history of breast cancer, baseline mammogram if due, and basic labs (lipids/glucose) as needed. Monitoring: regular follow‑ups (usually yearly), mammography as indicated, reassess ongoing need and lowest effective dose. Who to see: primary care physician, gynecologist, or a menopause clinic/endocrinologist. If you meant gender‑affirming HRT (transgender care) Age alone does not automatically prevent starting GAHT, but starting in your late 50s requires careful cardiovascular, thrombotic, prostate (for transfeminine), and metabolic risk assessment. Dosing and monitoring may be adjusted for older adults. Common medications: for transfeminine care — oral/transdermal estradiol (e.g., estradiol patches like Vivelle‑Dot) and often an antiandrogen (spironolactone or cyproterone in some countries); for transmasculine care — testosterone (topical gels like AndroGel or injections such as Nebido/testosterone undecanoate). Monitoring includes lipids, liver tests, hematocrit, and cardiovascular assessment. Best route is individualized; many trans health clinics and experienced endocrinologists provide tailored plans. Specific services/brands that might help Menopause clinics: North American Menopause Society (NAMS) directory and university menopause clinics (Mayo Clinic Menopause Clinic, Mount Sinai Menopause Program) — good for comprehensive evaluation and evidence‑based care. Pharmaceuticals/formulations commonly used: Vivelle‑Dot or Climara (estradiol patches — lower clot risk); Vagifem or Estring (local vaginal estrogen); Mirena (levonorgestrel IUD — endometrial protection + contraception for those who need it). Telehealth/trans care services (if you prefer remote care): Folx Health, Plume, or QTC (in the U.S.) — they provide evaluation and follow‑up for gender‑affirming HRT with protocols and monitoring. Labs/monitoring: national labs like Quest Diagnostics or LabCorp for baseline and follow‑up bloodwork. Next practical steps Tell me which HRT you mean (menopause vs gender‑affirming). Book an appointment with your PCP, gynecologist, or an endocrinologist/menopause specialist (or a reputable telehealth clinic if you prefer). Bring a list of your medical conditions, medications, family history, and your symptoms/goals. Ask about transdermal estradiol if you have clot/CV risk factors, and about an IUD if you still have a uterus and need progestogen coverage. If you want, tell me a bit about your health history (smoking, blood clots, heart disease, breast cancer in the family, how long since your last period, symptoms) and I can give more tailored information and suggest questions to ask your clinician.

Mentioned in position 8 of 16

Short answer: You may be in perimenopause if your periods and/or periods-of-monthly symptoms become irregular and you develop typical symptoms such as hot flashes, night sweats, sleep or mood changes, vaginal dryness, or brain fog. The only way to be sure (and to get safe treatment) is to discuss it with a clinician. What perimenopause is Perimenopause = the transition before menopause, when your ovaries make fewer and more variable sex hormones. It ends 12 months after your final menstrual period (that date = menopause). Common signs and symptoms Menstrual changes: cycles shorten or lengthen, bleedings heavier or lighter, skipped periods, spotting between periods. Irregular bleeding is the most common early clue. Vasomotor: hot flashes, night sweats. Sleep problems and fatigue. Mood: increased irritability, anxiety, or low mood. Vaginal/genitourinary: dryness, pain with sex, urinary frequency or urgency. Cognitive: trouble concentrating, memory “fog.” Other: reduced libido, joint aches, hair/skin changes, weight redistribution. Typical timing Most people start perimenopause in their 40s, but it can begin in the late 30s or earlier (surgical removal of ovaries or certain treatments can cause abrupt change). Can tests confirm it? Single blood tests aren’t definitive. FSH tends to rise as ovarian function declines, but it fluctuates during perimenopause so a single FSH may be normal. Estradiol and AMH can provide context but are also variable and not routinely diagnostic for perimenopause. Tests that are often useful: pregnancy test (if you could conceive), TSH (thyroid problems can mimic symptoms), CBC if heavy bleeding (check for anemia), and pelvic ultrasound or gynecology evaluation if bleeding is abnormal. Best approach: diagnosis is usually clinical — pattern of symptoms and menstrual changes over months. When to see a clinician urgently Very heavy bleeding (soaking a pad/tampon hourly for several hours), bleeding between periods that is new and heavy, severe pelvic pain, fainting, fever, or if symptoms severely affect daily life. Treatment and management options Lifestyle: sleep hygiene, regular exercise, limiting alcohol/caffeine, cooling strategies for hot flashes, quitting smoking, weight management. Vaginal/genitourinary symptoms: non-hormonal lubricants/moisturizers (Replens) or low‑dose local estrogen (vaginal estradiol cream, ring or tablet such as Estrace cream, Vagifem tablet, or Estring ring) — effective with minimal systemic exposure. Systemic hormone therapy (HRT) — most effective for hot flashes and bone protection. Forms include estradiol patches (Vivelle‑Dot or Climara), oral estradiol (Estrace), and combined products when you still have a uterus (progesterone like Prometrium or combined Prempro). HRT has benefits and risks (clotting, breast cancer risk varies by type/duration); discuss personal risks with your clinician. Nonhormonal medications for hot flashes: low‑dose paroxetine (Brisdelle — FDA‑approved), SSRIs/SNRIs (e.g., venlafaxine/Effexor), gabapentin (Neurontin), clonidine — useful if HRT isn’t an option. Consider bone health: discuss calcium, vitamin D, and bone density screening depending on age/risk. Practical next steps Track cycles and symptoms for 2–3 months (dates, flow, hot flashes, sleep, mood). Bring this to your visit. Do a pregnancy test if applicable. See your primary care provider or an OB/GYN. If you want menopause-focused care, look for a menopause clinic or specialist. Ask about blood tests (TSH, CBC, pregnancy, maybe FSH) and treatment options (local estrogen vs systemic HRT vs nonhormonal). Resources and services (trusted names) North American Menopause Society (NAMS, menopause.org) — authoritative patient/provider guidance. Mayo Clinic / Cleveland Clinic — reliable patient information pages about perimenopause and treatment. Gennev — telehealth and products focused on menopause care (convenient if you want specialists remotely). Maven Clinic — broad women’s health telemedicine with menopause/menstrual care options. Lab testing: Quest Diagnostics or Labcorp — widely used for blood tests ordered by clinicians. If you’d like, I can: Help you build a simple symptom tracker to bring to your doctor. Draft questions to ask a clinician about testing and treatment. Explain the specific risks and benefits of HRT given your age and medical history if you tell me more. Would you like a symptom tracker template or a list of questions to ask your clinician?

Mentioned in position 4 of 16

Short answer “Bioidentical” hormones are chemically identical to the hormones your body makes (usually estradiol, progesterone, testosterone). “Standard” HRT usually refers to FDA‑approved prescription preparations that may be bioidentical (e.g., estradiol) or non‑bioidentical/synthetic (e.g., conjugated equine estrogens, synthetic progestins). The big practical differences are regulation, quality control, evidence, and marketing claims — not a proven large difference in safety or effectiveness. Details — what each term means Bioidentical hormones: molecules with the same chemical structure as human hormones (for example 17β‑estradiol, micronized progesterone). They can be prescribed as FDA‑approved products (Estrace, Vivelle‑Dot, Prometrium, etc.) or made by compounding pharmacies into custom doses/creams/pellets (often marketed as “bioidentical hormone therapy” or BHRT). Standard HRT: commonly refers to traditional prescription hormone therapies used for menopause — some are bioidentical estradiol or progesterone formulations, others are non‑bioidentical (e.g., conjugated equine estrogens — Premarin; synthetic progestins such as medroxyprogesterone acetate — Provera). Regulation and quality FDA‑approved products (examples below) have standardized dosing, manufacturing oversight, and safety/efficacy data from clinical trials. Custom‑compounded bioidentical hormones are not FDA‑approved, can vary in potency and purity between pharmacies, and lack large randomized trial data. If you use compounding, choose a pharmacy with independent accreditation (look for Pharmacy Compounding Accreditation Board / ACHC accreditation). Safety and effectiveness Both bioidentical and non‑bioidentical hormones can relieve menopausal symptoms (hot flashes, vaginal dryness, sleep problems, etc.). Major risks (venous thromboembolism, stroke, possible breast cancer risk, gallbladder disease) depend on hormone type, dose, route, and patient risk factors. There is not strong, consistent evidence that compounded bioidentical hormones are safer than standard, FDA‑approved options. Some evidence suggests transdermal estradiol (patch or gel) carries lower blood‑clot risk than some oral estrogens — this is about route, not “bioidentical” label. Practical differences that matter Route: oral vs transdermal vs vaginal vs pellet — affects risks and side effects. Transdermal estradiol (patch/gel) tends to have lower VTE risk than oral estrogens. Progesterone: if you have a uterus you need a progestogen to prevent endometrial hyperplasia. Micronized progesterone (Prometrium) is a bioidentical, FDA‑approved option; alternative is levonorgestrel IUD (Mirena) or synthetic progestins (Provera). Testing/monitoring: beware clinics that rely on saliva hormone testing — it’s not reliable for guiding menopausal HRT. Decisions are usually based on symptoms, risk profile, and occasionally serum levels for specific situations. Named FDA‑approved products (examples you may see) Estradiol (bioidentical): Vivelle‑Dot, Climara, Minivelle (patches); Estrace (oral estradiol); Divigel, EstroGel (gels); Estring, Vagifem, Femring (vaginal products). Micronized progesterone (bioidentical): Prometrium (oral capsules). Non‑bioidentical/common older products: Premarin (conjugated equine estrogens), Provera (medroxyprogesterone acetate). Progestin IUD (effective for endometrium protection): Mirena (levonorgestrel). When to prefer one approach First line: discuss FDA‑approved options with your clinician. They have known safety profiles and consistent quality. Compounded bioidentical therapy may be chosen for specific dose/route needs or intolerances, but it carries more uncertainty — use only a reputable, accredited compounding pharmacy and discuss risks/benefits with your provider. Consider transdermal estradiol for people with higher clot risk (obesity, prior VTE) because of lower thrombosis signal in studies. What to ask your clinician Do I need estrogen? If so, what form and dose best match my symptoms and health risks? If I have a uterus, what progestogen will you recommend (micronized progesterone vs IUD vs synthetic progestin)? Why are you recommending an FDA‑approved product vs compounded BHRT? If compounded, which pharmacy do you use and is it accredited? Will you use symptom monitoring or labs to follow therapy? Resources and services For trustworthy guidance: North American Menopause Society (NAMS). If considering compounding, choose a pharmacy accredited by PCAB/ACHC. If you want a specific product to discuss with your clinician: Vivelle‑Dot or Climara (transdermal estradiol), Estrace (oral estradiol), Divigel (topical gel), Prometrium (micronized progesterone), Mirena (levonorgestrel IUD). Bottom line “Bioidentical” refers to chemical identity. The important decisions are product regulation (FDA vs compounded), route and dose, and your personal risks/benefits. Talk with a menopause‑experienced clinician to choose the safest, most effective option for you. If you’d like, tell me your symptoms, medical history (history of blood clots, breast cancer, liver disease, smoking, age), and whether you have a uterus — I can give more tailored comparisons.

Mentioned in position 10 of 17